Medexus Pharmaceuticals (MEDXF) News Today $1.70 +0.17 (+11.11%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Medexus Pharmaceuticals Inc. (MEDXF) Q2 2025 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comMedexus Pharmaceuticals Reports Strong Q2 2025 ResultsNovember 7, 2024 | markets.businessinsider.comMedexus Pharmaceuticals Inc. (MEDXF)August 22, 2024 | uk.finance.yahoo.comTSX:MDP (Medexus Pharmaceuticals)July 30, 2024 | fool.caCPHRF Cipher Pharmaceuticals Inc.May 3, 2024 | seekingalpha.comMDP:CA Medexus Pharmaceuticals Inc.April 3, 2024 | seekingalpha.comMedexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Slashed Next Year's EstimatesFebruary 12, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc.February 9, 2024 | wsj.comMedexus Pharmaceuticals just downgraded at Raymond James, here's whyFebruary 9, 2024 | realmoney.thestreet.comMedexus Announces Fiscal Q3 2024 ResultsFebruary 7, 2024 | finance.yahoo.comHealth Canada Accepts for Review Medexus's New Drug Submission for Topical TerbinafineJanuary 8, 2024 | finance.yahoo.comMEDXF Medexus Pharmaceuticals Inc.November 18, 2023 | seekingalpha.comMedexus Pharmaceuticals reports Q2 resultsNovember 8, 2023 | msn.comMedexus Fully Repays Convertible Debentures In Cash At MaturityOctober 16, 2023 | finance.yahoo.comMedexus and medac Agree to Amend US Treosulfan AgreementSeptember 28, 2023 | finance.yahoo.comMedexus Holds Annual Meeting of Shareholders and Announces Election of DirectorsSeptember 21, 2023 | finance.yahoo.comMedexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of UnitsSeptember 5, 2023 | finance.yahoo.comMedexus Pharmaceuticals Inc (MDP) Receives a Buy from Stifel NicolausSeptember 5, 2023 | markets.businessinsider.comMedexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion FacilitySeptember 5, 2023 | finance.yahoo.comMedexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia BAugust 17, 2023 | finance.yahoo.comMedexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 MillionAugust 9, 2023 | finance.yahoo.comMedexus Pharmaceuticals (MEDXF) Price Target Increased by 8.32% to 2.73August 2, 2023 | msn.comMedexus Schedules First Fiscal Quarter 2024 Conference CallAugust 2, 2023 | finance.yahoo.comMedexus Announces Preliminary Revenue for Fiscal Q1 2024July 12, 2023 | finance.yahoo.comFDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric PatientsJune 15, 2023 | finance.yahoo.comMedexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference CallJune 14, 2023 | finance.yahoo.comMedexus to Participate in the LD Micro Invitational XIIIJune 1, 2023 | finance.yahoo.comMedexus Pharmaceuticals Inc.: Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible DebenturesMay 10, 2023 | finanznachrichten.deMedexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible DebenturesMay 10, 2023 | finance.yahoo.comMedexus Expects Record Revenue for Fiscal Year 2023 and Provides Business UpdateApril 11, 2023 | finance.yahoo.comMedexus Announces New License Deal for Topical TerbinafineMarch 22, 2023 | finance.yahoo.comMedexus to Participate in 35th Annual Roth ConferenceMarch 6, 2023 | finance.yahoo.comMedexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022February 8, 2023 | finance.yahoo.comMedexus Secures Public Reimbursement for Cuvposa® in QuebecFebruary 1, 2023 | finance.yahoo.comMedexus Pharmaceuticals Inc: Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business UpdateJanuary 12, 2023 | finanznachrichten.deMedexus Pharmaceuticals FQ3 revenue to increase 34% Y/YJanuary 12, 2023 | msn.comMedexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business UpdateJanuary 12, 2023 | finance.yahoo.comMedexus Schedules Second Quarter 2023 Conference CallNovember 2, 2022 | finance.yahoo.comMedexus and MidCap Agree to Increase in MidCap's Revolving Loan Commitment AmountOctober 2, 2022 | marketwatch.comMedexus Pharma Says FDA Requests More Information for Treosulfan Drug ApplicationSeptember 19, 2022 | marketwatch.comMedexus Pharma Resubmits Treosulfan NDA To FDAJuly 25, 2022 | markets.businessinsider.comMedexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)June 22, 2022 | finance.yahoo.comMedexus Pharmaceuticals (OTC:MEDXF), Short Interest ReportJune 10, 2022 | benzinga.comMedexus Pharmaceuticals (OTC:MEDXF), Earnings Estimates, EPS, and RevenueJune 10, 2022 | benzinga.comAnalysts Expect Breakeven For Medexus Pharmaceuticals Inc. (TSE:MDP) Before LongMay 9, 2022 | finance.yahoo.comMedexus, medac refile seeking FDA nod for Treosulfan in cancer patients undergoing stem-cell transplantApril 22, 2022 | seekingalpha.comMedexus Pharmaceuticals Announces Resubmission of Treosulfan NDAApril 22, 2022 | finance.yahoo.comMedexus to Present at the Bloom Burton & Co. Healthcare Investor ConferenceApril 19, 2022 | finance.yahoo.comMedexus Pharmaceuticals reports FQ3 resultsFebruary 10, 2022 | seekingalpha.comMedexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021February 9, 2022 | finance.yahoo.com Get Medexus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MEDXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. MEDXF Media Mentions By Week MEDXF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MEDXF News Sentiment▼0.000.49▲Average Medical News Sentiment MEDXF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MEDXF Articles This Week▼00▲MEDXF Articles Average Week Get Medexus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MEDXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TGIFF News FFNTF News ABSCF News ACRHF News ACRDF News LBTSF News AZFL News ERBB News AWWH News AVTBF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MEDXF) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MEDXF Stock Alerts